Ventricular Arrhythmias Following Left Ventricular Assist Device Placement: Can We Predict Them?
Abdelrahman Abdelaal, MBBCch, Ahmed Nafea, MBBCch
Faculty of Medicine, Alexandria University

Aims:

With the growing number of patients suffering from heart failure worldwide and the short supply of donor hearts for transplantation, left ventricular assist devices (LVAD) remain an option and a well-established treatment for patients with advanced heart failure. One of the main problems facing LVAD, however, is the high prevalence of ventricular arrhythmias after their implantation.

The aim of this review is to:
- Identify the main risk factors of ventricular arrhythmias post LVAD implantation.
- Identify the likelihood of the occurrence of VA in those patients.

Methods:

Literature research was done on PubMed, Web of Science, Cochrane, and Scopus in March 2022. The following combined terms were used: “LVAD” or “left ventricular assist device” or “heart assist device” and “ventricular arrhythmia” or “arrhythmia,” “ventricular tachycardia,” or “ventricular fibrillation” as either keywords or MeSH terms. Studies were then reviewed for their relevance and non-relevant ones were excluded.

Results:

Thirteen studies were included in this review. The combined odds ratio showed that the greatest predictor of VA post LVAD implantation was VA before implantation. In addition, other independent risk factors included atrial fibrillation before LVAD, the lack of angiotensin converting enzyme inhibitors (ACEI) use after implantation, idiopathic cardiomyopathy, and heart failure of more than 12 months duration.

Galand et al suggested that early VA less than 30 days after LVAD implantation can be a risk factor of late VA, and Greet et al found that prior cardiac surgery, in particular coronary artery bypass graft surgery, was a risk factors of VA. Rehorn et al found that ventricular tachycardia ablation and the use of antiarrhythmics before LVAD to be a risk factor for the development of late VA. Enriquez et al uniquely found that perioperative mechanical circulatory support was a risk factor for the development of electrical storm.

Many other predictors were investigated including basic demographics and comorbidities including age, sex, arterial hypertension, dyslipidemia, and even the type of LVAD used, but none were statistically significant to indicate a higher incidence of VA between groups.

Conclusions:

Identifying risk factors of VA before LVAD implantation can guide future indications of implantable cardioverter device (ICD) in patients who did not have it before. Although a large number of patients have ICD by the time of LVAD placement, the placement of ICD before for patient who did not have it before remains an uncertain subject. VA ablation also remains a viable option for many patients before LVAD placement, and to guide the indications for its use, it is important to balance its benefits against risks which have been reported to include the risk of pump thrombosis, although it is worth mentioning that the number of studies suggesting it is scarce.